FDA approves a liquid form of Kamada's AATD drug Glassia

07/5/2010 | Reuters

The FDA approved a liquid version of Glassia, Kamada's intravenous drug for alpha-1 antitrypsin deficiency, a condition that can lead to lung-tissue damage and emphysema. Kamada said it is looking for a partner to develop the treatment for other indications.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX